Balyasnikova I V, Danilov S M, Muzykantov V R, Fisher A B
Institute for Environmental Medicine, University of Pennsylvania, Philadelphia, USA.
In Vitro Cell Dev Biol Anim. 1998 Jul-Aug;34(7):545-54. doi: 10.1007/s11626-998-0114-x.
Previous work has suggested that not all immunoreactive angiotensin-converting enzyme (ACE) in tissues or cells is in a biologically active state. We have explored this possibility in cultured human umbilical vein endothelial cells (HUVEC), one of the most widely studied in vitro endothelial cell systems. Our approach included characterization of the effect of increasing passage number on ACE activity and expression of immunoreactive ACE at the single cell level, the subcellular compartmentalization of active ACE, and the effect of phorbol ester (PMA) treatment. We found that both ACE activity and expression of ACE antigen were downregulated by cultivation (30% of ACE-positive cells at seventh passage vs. 90% in primary culture). ACE downregulation is specific (number of CD31-positive cells did not change with cultivation) and correlated with downregulation of factor VIII-antigen. The percentage of ACE-positive cells in permeabilized HUVEC at third passage was almost twice that in nonpermeabilized HUVEC (90% vs. 50%), indicating that HUVEC contain intracellular immunoreactive ACE. ACE activity, however, was similar when measured in intact cells and in cell lysates. Moreover, diazonium salt of sulfanilic acid (DASA), a membrane-impermeable ACE inhibitor, inhibited ACE activity in intact cells and in cell lysates at the same extent, thus implying that intracellular ACE is inactive. PMA (100 nM) treatment increased the percentage of ACE-positive cells at third passage from 57 to 96%. ACE activity was increased 3-fold in cell and 1.5-fold in the culture medium of PMA-treated cells. Analysis of ACE activity in intact monolayers and cell lysates of control and PMA-treated cells revealed that all enzymatically active ACE in PMA-treated cells is localized on the plasma membrane and acts as an ectoenzyme. We conclude that expression of ACE by HUVEC is downregulated by repeated passage in culture but can be restored by PMA treatment. In addition, ACE expression is heterogeneous between neighboring cells, and total immunoreactive ACE protein associated with HUVEC includes an inactive pool of the enzyme.
先前的研究表明,组织或细胞中的并非所有免疫反应性血管紧张素转换酶(ACE)都处于生物活性状态。我们在培养的人脐静脉内皮细胞(HUVEC)中探讨了这种可能性,HUVEC是体外研究最广泛的内皮细胞系统之一。我们的方法包括在单细胞水平上表征传代次数增加对ACE活性和免疫反应性ACE表达的影响、活性ACE的亚细胞分隔以及佛波酯(PMA)处理的影响。我们发现,培养会使ACE活性和ACE抗原表达下调(第七代时30%的ACE阳性细胞,而原代培养时为90%)。ACE下调具有特异性(CD31阳性细胞数量不会随培养而改变),且与因子VIII抗原的下调相关。第三代透化HUVEC中ACE阳性细胞的百分比几乎是非透化HUVEC中的两倍(90%对50%),表明HUVEC含有细胞内免疫反应性ACE。然而,在完整细胞和细胞裂解物中测量时,ACE活性相似。此外,膜不可渗透的ACE抑制剂对氨基苯磺酸重氮盐(DASA)在相同程度上抑制完整细胞和细胞裂解物中的ACE活性,因此意味着细胞内ACE无活性。PMA(100 nM)处理使第三代ACE阳性细胞的百分比从57%增加到96%。PMA处理的细胞中,细胞内ACE活性增加3倍,培养基中增加1.5倍。对对照和PMA处理细胞的完整单层和细胞裂解物中的ACE活性分析表明,PMA处理细胞中所有具有酶活性的ACE都定位于质膜并作为一种外切酶起作用。我们得出结论,HUVEC中ACE的表达在培养过程中通过反复传代而下调,但可通过PMA处理恢复。此外,相邻细胞之间ACE表达存在异质性,与HUVEC相关的总免疫反应性ACE蛋白包括该酶的无活性库。